Sun, Apr 20, 2014, 8:40 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Savient Pharmaceuticals, Inc. Message Board

  • bobandnor bobandnor Oct 27, 2008 11:54 AM Flag

    Only 50k patients for drug-yikes!!

    sell sell sell -company cannot even recoup all the money spent on fda approval- What a waste of money!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • At 20K a year per patient it is $1 billion. Then you have the EU and Asian populations. Then if they give an indication just for tophi you can break into the general gout poopulation beyond the orphan population. That would probably be out of a 500K patient pool. Someone who went to the conference posted earlier that $20K/year/patient is what they were thinking on price.

    • The population has been pegged at 50k since the onset. If you didnt like the population then, it shouldnt change your opinion now.

      What has changed with this drug? The only thing I see is three additional people with preexisting heart disease - had heart attacks. This is reason for pause - but not reason to throw the drug out. The placebo group had an even greater heart attack experience.

      I change my opinion when either FDA approval looks in doubt - seems unlikely since they are pushing the drug for other apps. Or if the efficacy of the drug begins to change - but the contrary seems to be occurring.

 
SVNTQ
0.0062+0.0001(+1.64%)Apr 17 3:22 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT
Pfizer Inc.
NYSEThu, Apr 17, 2014 4:00 PM EDT